Licensing and Regulatory Changes for Cosmetics and Quasi-Drugs
First written in FY2016. 4 of 8 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Expansion of regulatory scopeAnnual report
「In addition, if we are unable to adapt to the revision, abolition or enactment of laws and regulations, including the Act on the Promotion of Proper Transactions for Small and Medium-sized Entrusted Businesses, the Act against Unjustifiable Premiums and Misleading Representations, and the Act on the Protection of Personal Information, or if we fail to comply with legal regulations, our business activities may be restricted and our operating results, financial position and other factors may be affected.」
In addition to the existing risks related to cosmetics permits and laws concerning relaxation services, the disclosure specifies risks related to regulatory changes and compliance, including proper entrusted transactions, representations concerning premiums and personal information protection. - FY2023RestatedAnnual report
「The marketing authorizations are both valid from 11 March 2022 to 10 March 2027.」
The validity of the marketing authorizations for cosmetics and quasi-drugs through 10 March 2027, as well as the risks of expiration, revocation and other events affecting the authorizations, is reiterated. - FY2022MitigatedAnnual report
「The marketing authorizations are both valid from 11 March 2022 to 10 March 2027.」
The marketing authorizations for cosmetics and quasi-drugs were renewed, extending their validity through 10 March 2027. - FY2021RestatedAnnual report
「The marketing authorizations are both valid from 11 March 2017 to 10 March 2022.」
The validity of the marketing authorizations for cosmetics and quasi-drugs through 10 March 2022, as well as the risks of expiration, revocation and other events affecting the authorizations, is reiterated. - FY2020RestatedAnnual report
「The marketing authorizations are both valid from 11 March 2017 to 10 March 2022.」
The validity of the marketing authorizations for cosmetics and quasi-drugs through 10 March 2022, as well as the risks of expiration, revocation and other events affecting the authorizations, is reiterated. - FY2019RestatedAnnual report
「The marketing authorizations are both valid from 11 March 2017 to 10 March 2022.」
The validity of the marketing authorizations for cosmetics and quasi-drugs through 10 March 2022 is reiterated. - FY2017MitigatedAnnual report
「The marketing authorizations for cosmetics and quasi-drugs are both valid from 11 March 2017 to 10 March 2022.」
The marketing authorizations for cosmetics and quasi-drugs were renewed, with their validity periods stated as running through 10 March 2022. - FY2016First statedAnnual report
「As stated above, the continuation of our principal business activities requires a marketing authorization for cosmetics and quasi-drugs. We must therefore conduct our business in compliance with the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices and other applicable laws and regulations. At present, we understand that there are no facts indicating that we are subject to revocation of the relevant authorization or failure to meet its renewal requirements.」
The disclosure identifies the expiration or revocation of marketing authorizations, failure to meet renewal requirements, and business restrictions resulting from the revision, abolition or enactment of laws and regulations as risks. It also discloses that the authorization was valid from 11 March 2012 to 10 March 2017.